I-Mab Announces Upcoming Participation at November Conferences
I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several upcoming investor conferences in November 2020. Notable events include the 11th Credit Suisse China Investment Conference and the 15th Citi China Investor Conference, where management will engage in one-on-one meetings. The company aims to showcase its innovative pipeline in immuno-oncology and autoimmune diseases, emphasizing its shift towards becoming a fully integrated global biopharmaceutical company. For more details, visit I-Mab's website.
- Participation in multiple investor conferences may enhance visibility and investor interest in IMAB.
- I-Mab is developing a diverse pipeline of over 10 clinical and pre-clinical candidates, indicating robust R&D efforts.
- The company is transitioning towards becoming a fully integrated global biopharmaceutical company.
- None.
SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in November. Details of the conferences and management presentation are as follows:
11th Credit Suisse China Investment Conference (Virtual)
Management participants: Mr. Jielun Zhu, Director and Chief Financial Officer and Ms. Leah Liu, Senior IR Director
One-on-one and small group meetings: November 2 & 5, 2020
For more information, please contact your Credit Suisse representative.
15th Citi China Investor Conference 2020 (Virtual)
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director
One-on-one and small group meetings: November 3-5, 2020
For more information, please contact your Citi representative.
CICC Investment Forum (Beijing) 2020
Management participant: Mr. Jielun Zhu, Director and Chief Financial Officer
Location: Kerry Hotel, Beijing, China
One-on-one and small group meetings: November 11-12, 2020
For more information, please contact your CICC representative.
Nomura Investment Forum 2020 (Virtual)
Management participants: Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director
Large group meetings: November 13, 2020
For more information, please contact your Nomura representative.
Goldman Sachs Asia Pacific Healthcare Forum 2020 (Virtual)
Panel Discussion: Tuesday, November 17, 2020 at 10:00 a.m. HKT
Panelist: Dr. Joan Huaqiong Shen, Director and Chief Executive Officer
One-on-one and small group meetings: November 16-18, 2020
Management participants: Mr. Jielun Zhu, Director and Chief Financial Officer and Ms. Leah Liu, Senior IR Director
For more information, please contact your Goldman Sachs representative.
Jefferies London Healthcare Conference (Virtual)
Presentation: Tuesday, November 17, 2020 at 12:55-1:25 p.m. GMT
Presenter: Dr. Joan Huaqiong Shen, Director and Chief Executive Officer
Webcast link: https://wsw.com/webcast/jeff141/imab/1814025 The webcast will also be available under "Event Calendar" on IMAB's IR website at http://ir.i-mabbiopharma.com/ .
One-on-one meetings: November 17-19, 2020
Management participants: Dr. Jingwu Zang, Founder, Honorary Chairman and Director, Dr. Joan Huaqiong Shen, Director and Chief Executive Officer, Mr. Jielun Zhu, Director and Chief Financial Officer, and Ms. Leah Liu, Senior IR Director
For more information, please contact your Jefferies representative.
About I-Mab
I-Mab (Nasdaq: IMAB) is a dynamic, global biotech company exclusively focused on discovery, development and soon commercialization of novel or highly differentiated biologics in the therapeutic areas of immuno-oncology and autoimmune diseases. The Company's mission is to bring transformational medicines to patients around the world through innovation. I-Mab's innovative pipeline of more than 10 clinical and pre-clinical stage drug candidates is driven by the Company's Fast-to-PoC (Proof-of-Concept) and Fast-to-Market development strategies through internal R&D and global partnerships. The Company is on track to transitioning from a clinical stage biotech company toward a fully integrated global biopharmaceutical company with cutting-edge R&D capabilities, world-class GMP manufacturing facility and commercial capability. I-Mab has offices in Beijing, Shanghai, Hangzhou, Hong Kong and Maryland, United States. For more information, please visit http://ir.i-mabbiopharma.com and follow I-Mab on LinkedIn and WeChat.
For more information, please contact:
I-Mab
Jielun Zhu, Chief Financial Officer
E-mail: jielun.zhu@i-mabbiopharma.com
Office line: +86 21 6057 8000
Gigi Feng, Chief Communications Officer
E-mail: gigi.feng@i-mabbiopharma.com
Office line: +86 21 6057 8000
Investor Inquiries:
Burns McClellan, Inc. (Americas and Europe)
Steve Klass
E-mail: sklass@burnsmc.com
Office line: +1 212 213 0006
The Piacente Group, Inc. (Asia)
Emilie Wu
E-mail: emilie@thepiacentegroup.com
Office line: + 86 21 6039 8363
View original content to download multimedia:http://www.prnewswire.com/news-releases/i-mab-announces-upcoming-participation-at-november-conferences-301161665.html
SOURCE I-Mab
FAQ
What conferences is I-Mab participating in November 2020?
Who will represent I-Mab at the upcoming investor conferences?
What is the focus of I-Mab's drug development?
Where can I find more information about I-Mab's participation in the conferences?
What is I-Mab's stock symbol?
